Biocon has announced that the European Commission (EC) has granted marketing authorisation for Pebrilzo, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU).
Biocon’s pertuzumab biosimilar is the first biosimilar to receive EC marketing authorisation under the European Medicines Agency’s (EMA) new tailored clinical approach. The approval follows the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) on September 17, 2026.
Commenting on the approval, Shreehas Tambe, CEO and Managing Director, Biocon, said, “The European Commission’s approval of Pebrilzo, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon. With this approval, pertuzumab becomes our fifth oncology biosimilar approved in both Europe and the United States, strengthening our global oncology portfolio and reinforcing our commitment to expanding access to high-quality, affordable biologic therapies for patients with HER2-positive breast cancer.”
Biocon’s pertuzumab biosimilar has been approved as a 420 mg concentrate for solution for infusion. Its active substance, pertuzumab, is a monoclonal antibody that binds with high affinity and specificity to the human epidermal growth factor receptor 2 (HER2), inhibiting the proliferation of tumour cells that overexpress HER2.
The biosimilar is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence. It is also indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.
In addition, the biosimilar is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
According to Biocon, extensive orthogonal, state-of-the-art structural and functional analytical characterisation, together with comparative clinical pharmacokinetic data, demonstrated that its pertuzumab biosimilar is highly similar to the reference product, with no clinically meaningful differences in quality, safety or efficacy.